Literature DB >> 11981563

An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity.

Paolo Michieli1, Silvia Cavassa, Cristina Basilico, Annarita De Luca, Massimiliano Mazzone, Cinzia Asti, Riccardo Chiusaroli, Mario Guglielmi, Paola Bossù, Francesco Colotta, Gianfranco Caselli, Paolo M Comoglio.   

Abstract

Hepatocyte growth factor (HGF) and macrophage-stimulating protein (MSP) have an intrinsic dual nature: they are trophic cytokines preventing apoptosis on one side and scatter factors promoting invasion on the other. For therapeutic use, their anti-apoptotic activity must be separated from their pro-invasive activity. To this end, we engineered chimeric factors containing selected functional domains of HGF and/or MSP in different combinations, and tested their biological activity. Here we present a chimeric cytokine derived from the alpha-chains of HGF and MSP, named Metron factor 1 for its ability to concomitantly activate the HGF receptor (Met) and the MSP receptor (Ron). We provide evidence that Metron factor 1 prevents apoptosis and stimulates cell proliferation at nanomolar concentrations, but is devoid of any pro-invasive activity. In an in vivo murine model of drug-induced nephrotoxicity, intravenous injection of recombinant Metron factor 1 prevented renal damage and preserved tubular integrity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981563     DOI: 10.1038/nbt0502-488

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  6 in total

1.  Delivery of an engineered HGF fragment in an extracellular matrix-derived hydrogel prevents negative LV remodeling post-myocardial infarction.

Authors:  Sonya B Sonnenberg; Aboli A Rane; Cassie J Liu; Nikhil Rao; Gillie Agmon; Sophia Suarez; Raymond Wang; Adam Munoz; Vaibhav Bajaj; Shirley Zhang; Rebecca Braden; Pamela J Schup-Magoffin; Oi Ling Kwan; Anthony N DeMaria; Jennifer R Cochran; Karen L Christman
Journal:  Biomaterials       Date:  2015-01-13       Impact factor: 12.479

2.  Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody.

Authors:  Giovanni Pacchiana; Cristina Chiriaco; Maria C Stella; Fiorella Petronzelli; Rita De Santis; Maria Galluzzo; Paolo Carminati; Paolo M Comoglio; Paolo Michieli; Elisa Vigna
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

3.  Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists.

Authors:  Douglas S Jones; Ping-Chuan Tsai; Jennifer R Cochran
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

4.  Magic-factor 1, a partial agonist of Met, induces muscle hypertrophy by protecting myogenic progenitors from apoptosis.

Authors:  Marco Cassano; Stefano Biressi; Amanda Finan; Laura Benedetti; Claudia Omes; Renata Boratto; Frank Martin; Marcello Allegretti; Vania Broccoli; Gabriella Cusella De Angelis; Paolo M Comoglio; Cristina Basilico; Yvan Torrente; Paolo Michieli; Giulio Cossu; Maurilio Sampaolesi
Journal:  PLoS One       Date:  2008-09-16       Impact factor: 3.240

5.  A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.

Authors:  Cristina Basilico; Addolorata Arnesano; Maria Galluzzo; Paolo M Comoglio; Paolo Michieli
Journal:  J Biol Chem       Date:  2008-05-21       Impact factor: 5.157

6.  Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.

Authors:  Marie Godar; Virginia Morello; Ava Sadi; Anna Hultberg; Natalie De Jonge; Cristina Basilico; Valérie Hanssens; Michael Saunders; Bart N Lambrecht; Mohamed El Khattabi; Hans de Haard; Paolo Michieli; Christophe Blanchetot
Journal:  Sci Rep       Date:  2016-08-22       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.